NASDAQ:VRUS - Pharmasset Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.01 0.00 (0.00 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$0.0112
Today's Range$0.0085 - $0.0165
52-Week Range$0.0008 - $0.0180
Volume127.37 million shs
Average Volume23.94 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.

Receive VRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VRUS
CUSIPN/A
WebN/A
Phone+1-609-6134100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Pharmasset (NASDAQ:VRUS) Frequently Asked Questions

What is Pharmasset's stock symbol?

Pharmasset trades on the NASDAQ under the ticker symbol "VRUS."

Has Pharmasset been receiving favorable news coverage?

News stories about VRUS stock have been trending positive on Saturday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pharmasset earned a news impact score of 2.6 on InfoTrie's scale. They also assigned headlines about the healthcare company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near future.

What other stocks do shareholders of Pharmasset own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmasset investors own include Alkaline Water (WTER), Medmen Enterprises (MMNFF), HPIL (HPIL), Titan Pharmaceuticals (TTNP), Del Taco Restaurants (TACO), Magnegas Applied Tchnlgy Sltns (MNGA), Amarin (AMRN) and Advanced Micro Devices (AMD).

How do I buy shares of Pharmasset?

Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharmasset's stock price today?

One share of VRUS stock can currently be purchased for approximately $0.0112.

How can I contact Pharmasset?

Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100.


MarketBeat Community Rating for Pharmasset (NASDAQ VRUS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel